Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Omega Therapeutics provides update on upcoming milestones » 07:13
09/10/21
09/10
07:13
09/10/21
07:13
OMGA

Omega Therapeutics

$20.32 /

-0.15 (-0.73%)

Omega Therapeutics…

Omega Therapeutics upcoming milestones and key priorities: complete IND-enabling studies for OTX-2002 and successfully file IND application to FDA during the first half of 2022; nominate additional OEC development candidates in the first half of 2022; file a second IND application targeted for second half of 2022; continue to develop the OMEGA Epigenomic Programming platform and investigate additional development programs to expand pipeline; and publish relevant pre-clinical and early clinical data supporting our programs and platform development.

ShowHide Related Items >><<
OMGA Omega Therapeutics
$20.32 /

-0.15 (-0.73%)

08/24/21
Fly Intel: Top five analyst initiations
08/24/21 Wedbush
Wedbush bullish on Omega Therapeutics, initiates with an Outperform
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
OMGA Omega Therapeutics
$20.32 /

-0.15 (-0.73%)

  • 30
    Jul
OMGA Omega Therapeutics
$20.32 /

-0.15 (-0.73%)

Earnings
Omega Therapeutics reports Q2 EPS ($3.36), consensus ($1.21) » 07:12
09/10/21
09/10
07:12
09/10/21
07:12
OMGA

Omega Therapeutics

$20.32 /

-0.15 (-0.73%)

"Our recent…

"Our recent successful initial public offering reinforces our commitment to bring potentially transformative programmable mRNA therapeutics that target the epigenetic basis of disease to precisely control gene expression to patients across a wide range of diseases. We are thrilled to bring in new investors through our IPO and to have the continued support of our existing stockholders," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "The funding provides the necessary financial resources to advance our lead Omega Epigenomic Controller candidate, OTX-2002, for the treatment of Hepatocellular Carcinoma through an Investigational New Drug filing and initial clinical readouts, as well as to continue pre-clinical and IND-enabling studies for several additional OEC development candidates."

ShowHide Related Items >><<
OMGA Omega Therapeutics
$20.32 /

-0.15 (-0.73%)

08/24/21
Fly Intel: Top five analyst initiations
08/24/21 Wedbush
Wedbush bullish on Omega Therapeutics, initiates with an Outperform
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
  • 30
    Jul
OMGA Omega Therapeutics
$20.32 /

-0.15 (-0.73%)

Initiation
Fly Intel: Top five analyst initiations » 09:54
08/24/21
08/24
09:54
08/24/21
09:54
OMGA

Omega Therapeutics

$22.09 /

-0.03 (-0.14%)

, DOLE

Dole

$16.41 /

+0.37 (+2.31%)

, PACK

Ranpak Holdings

$31.29 /

-0.06 (-0.19%)

, COIN

Coinbase

$254.18 /

-1.64 (-0.64%)

, MXCT

MaxCyte

$14.41 /

+0.06 (+0.42%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Omega Therapeutics (OMGA) initiated with a Buy at Jefferies and an Outperform at Wedbush. 2. Dole (DOLE) initiated with a Buy at Goldman Sachs and Deutsche Bank, initiated with an Overweight at Stephens, a Market Perform at BMO Capital and an Underperform at BofA. 3. Ranpak Holdings (PACK) initiated with a Neutral at Goldman Sachs. 4. Coinbase (COIN) initiated with Buy at Needham. 5. MaxCyte (MXCT) initiated with a Buy at Stifel and BTIG, initiated with an Outperform at Cowen, and William Blair and initiated with an Overweight at Stephens. click here.

ShowHide Related Items >><<
PACK Ranpak Holdings
$31.29 /

-0.06 (-0.19%)

MXCT MaxCyte
$14.41 /

+0.06 (+0.42%)

COIN Coinbase
$254.18 /

-1.64 (-0.64%)

OMGA Omega Therapeutics
$22.09 /

-0.03 (-0.14%)

08/24/21 Wedbush
Wedbush bullish on Omega Therapeutics, initiates with an Outperform
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
DOLE Dole
$16.41 /

+0.37 (+2.31%)

08/24/21 BofA
BofA starts Dole at Underperform, says stock 'not ripe enough'
08/24/21 Stephens
Dole initiated with an Overweight at Stephens
08/24/21 Stephens
Dole initiated with an Overweight at Stephens
08/24/21 BofA
Dole initiated with an Underperform at BofA
PACK Ranpak Holdings
$31.29 /

-0.06 (-0.19%)

08/24/21 Goldman Sachs
Ranpak Holdings initiated with a Neutral at Goldman Sachs
08/10/21 Baird
Ranpak Holdings initiated with an Outperform at Baird
08/10/21 Baird
Ranpak Holdings initiated with an Outperform at Baird
04/26/21 Berenberg
Ranpak Holdings initiated with a Buy at Berenberg
COIN Coinbase
$254.18 /

-1.64 (-0.64%)

08/24/21 Needham
Coinbase initiated with Buy, $420 price target at Needham
08/18/21 Mizuho
Mizuho sees signs that could 'tame' Coinbase investor enthusiasm
08/13/21 BofA
Coinbase initiated with a Neutral at BofA
08/11/21 Keefe Bruyette
Coinbase price target raised to $275 from $265 at Keefe Bruyette
MXCT MaxCyte
$14.41 /

+0.06 (+0.42%)

08/24/21 Stephens
MaxCyte initiated with an Overweight at Stephens
08/24/21 William Blair
Blair starts MaxCyte at Outperform, sees 'one-of-a-kind opportunity'
08/24/21 William Blair
MaxCyte initiated with an Outperform at William Blair
08/24/21 Stephens
MaxCyte initiated with an Overweight at Stephens
PACK Ranpak Holdings
$31.29 /

-0.06 (-0.19%)

COIN Coinbase
$254.18 /

-1.64 (-0.64%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 27
    May
  • 14
    Apr
DOLE Dole
$16.41 /

+0.37 (+2.31%)

COIN Coinbase
$254.18 /

-1.64 (-0.64%)

OMGA Omega Therapeutics
$22.09 /

-0.03 (-0.14%)

COIN Coinbase
$254.18 /

-1.64 (-0.64%)

COIN Coinbase
$254.18 /

-1.64 (-0.64%)

Initiation
Wedbush bullish on Omega Therapeutics, initiates with an Outperform » 08:28
08/24/21
08/24
08:28
08/24/21
08:28
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

As previously reported,…

As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Omega Therapeutics with an Outperform rating and $36 price target. The analyst sees potential for significant value creation as Omega's pipeline of development programs progress into the clinic, and as the platform applies learnings to additional high value indications going forward.

ShowHide Related Items >><<
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Piper Sandler
Omega Therapeutics initiated with an Overweight at Piper Sandler
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Initiation
Omega Therapeutics initiated with a Buy at Jefferies » 07:33
08/24/21
08/24
07:33
08/24/21
07:33
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Omega Therapeutics with a Buy rating and $30 price target. Omega is an early-stage platform company developing new class medicines termed "epigenetic controllers," and Howerton tells investors in a research note that its lead programs target c-Myc, which if successful could represent a $4B opportunity in Liver/Lung cancers alone.

ShowHide Related Items >><<
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

08/24/21 Wedbush
Omega Therapeutics initiated with an Outperform at Wedbush
08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Piper Sandler
Omega Therapeutics initiated with an Overweight at Piper Sandler
08/24/21 Goldman Sachs
Omega Therapeutics initiated with a Neutral at Goldman Sachs
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Initiation
Omega Therapeutics initiated with an Outperform at Wedbush » 06:50
08/24/21
08/24
06:50
08/24/21
06:50
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll initiated coverage of Omega Therapeutics with an Outperform rating and $36 price target.

ShowHide Related Items >><<
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

08/24/21 Jefferies
Omega Therapeutics initiated with a Buy at Jefferies
08/24/21 Piper Sandler
Omega Therapeutics initiated with an Overweight at Piper Sandler
08/24/21 Goldman Sachs
Omega Therapeutics initiated with a Neutral at Goldman Sachs
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Initiation
Omega Therapeutics initiated with a Buy at Jefferies » 06:28
08/24/21
08/24
06:28
08/24/21
06:28
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Omega Therapeutics with a Buy rating and $30 price target.

ShowHide Related Items >><<
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

08/24/21 Piper Sandler
Omega Therapeutics initiated with an Overweight at Piper Sandler
08/24/21 Goldman Sachs
Omega Therapeutics initiated with a Neutral at Goldman Sachs
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Initiation
Omega Therapeutics initiated with an Overweight at Piper Sandler » 05:04
08/24/21
08/24
05:04
08/24/21
05:04
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff initiated coverage of Omega Therapeutics with an Overweight rating and $30 price target. Omega is pioneering the development of a novel class of mRNA-encoded medicines, targeting specific insulated genomic domains to correct expression of disease-causing genes, Tenthoff tells investors in a research note. The analyst says the company "rationally designs" modular Omega Epigenomic Controllers to precisely control the level and duration of expression of specific genes. He sees "enormous potential for this novel therapeutic modality to treat a broad range of diseases."

ShowHide Related Items >><<
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

08/24/21 Goldman Sachs
Omega Therapeutics initiated with a Neutral at Goldman Sachs
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Initiation
Omega Therapeutics initiated with a Neutral at Goldman Sachs » 05:00
08/24/21
08/24
05:00
08/24/21
05:00
OMGA

Omega Therapeutics

$22.12 /

+0.18 (+0.82%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Omega Therapeutics with a Neutral rating and $22 price target. The analyst is positive on Omega's "potentially revolutionary and unique" technology, preclinical data and "de-risked" LNP delivery system, but says its pipeline is early and lacks near-term value driving catalysts.

ShowHide Related Items >><<
  • 30
    Jul
OMGA Omega Therapeutics
$22.12 /

+0.18 (+0.82%)

Over a month ago
On The Fly
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:27
08/21/21
08/21
08:27
08/21/21
08:27
ARBK

Argo Blockchain

/

+

, ARBKF

Argo Blockchain

$1.83 /

+0.15 (+8.93%)

, PRCT

Procept BioRobotics

/

+

, SRAD

Sportradar

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, BLK

BlackRock

$917.42 /

+14.44 (+1.60%)

, SPG

Simon Property

$128.78 /

+0.35 (+0.27%)

, MS

Morgan Stanley

$100.71 /

+1.01 (+1.01%)

, GS

Goldman Sachs

$396.03 /

+2.76 (+0.70%)

, BCS

Barclays

$9.96 /

+0.01 (+0.10%)

, BAC

Bank of America

$40.38 /

+0.195 (+0.49%)

, MXCT

MaxCyte

$14.39 /

+0.61 (+4.43%)

, RXST

RxSight

$11.89 /

-0.175 (-1.45%)

, TNYA

Tenaya Therapeutics

$22.31 /

+1.41 (+6.75%)

, RANI

Rani Therapeutics

$16.11 /

-0.93 (-5.46%)

, NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

, ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

, RSKD

Riskified

$28.61 /

+1.445 (+5.32%)

, OMGA

Omega Therapeutics

$21.94 /

-0.09 (-0.41%)

, IMRX

Immuneering

$30.23 /

-0.53 (-1.72%)

, INAB

In8bio

$7.64 /

-0.22 (-2.80%)

, HOOD

Robinhood

$42.62 /

-1.99 (-4.46%)

, RLYB

Rallybio

$12.57 /

-0.23 (-1.80%)

, ABVC

ABVC BioPharma

$2.03 /

-0.12 (-5.58%)

In a quiet week for IPOs,…

ShowHide Related Items >><<
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

ARBK Argo Blockchain
/

+

ARBKF Argo Blockchain
$1.83 /

+0.15 (+8.93%)

06/01/21 H.C. Wainwright
Argo Blockchain initiated with a Buy at H.C. Wainwright
PRCT Procept BioRobotics
/

+

SRAD Sportradar
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

08/16/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Morgan Stanley
Simon Property price target raised to $161 from $150 at Morgan Stanley
08/04/21 BofA
Simon Property upgraded to Buy from Neutral at BofA
MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral at Seaport Global on valuation
08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral from Buy at Seaport Global
07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.96 /

+0.01 (+0.10%)

08/02/21 RBC Capital
Barclays price target raised to 190 GBp from 180 GBp at RBC Capital
07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
BAC Bank of America
$40.38 /

+0.195 (+0.49%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

TNYA Tenaya Therapeutics
$22.31 /

+1.41 (+6.75%)

RANI Rani Therapeutics
$16.11 /

-0.93 (-5.46%)

NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

RSKD Riskified
$28.61 /

+1.445 (+5.32%)

OMGA Omega Therapeutics
$21.94 /

-0.09 (-0.41%)

IMRX Immuneering
$30.23 /

-0.53 (-1.72%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

08/17/21 Redburn
Redburn starts Robinhood at Buy with fair value implying 29% upside
08/17/21 Redburn
Robinhood initiated with a Buy at Redburn
08/05/21 Wolfe Research
Robinhood initiated with a Peer Perform at Wolfe Research
07/29/21
Fly Intel: Top five analyst initiations
RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 29
    Jul
  • 16
    Jul
  • 19
    Nov
  • 13
    Nov
SRAD Sportradar
/

+

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SRAD Sportradar
/

+

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

QNIU Qiniu
/

+

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.